Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Iodine Supplementation in Graves' Hyperthyroidism
NCT06540469Not yet recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Aug 2024
- Primary completion
- Jul 2027
01
Overview
Randomised, open-label trial (3 arms), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoint: Remission rate of hyperthyroidism at 30 months. Planned start Aug 2024; status: not yet recruiting.
Beyond the preview
Go deeper on NCT06540469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06540469.